PL3054959T3 - Sposoby leczenia złośliwych nowotworów zwłóknieniowych - Google Patents

Sposoby leczenia złośliwych nowotworów zwłóknieniowych

Info

Publication number
PL3054959T3
PL3054959T3 PL14851638T PL14851638T PL3054959T3 PL 3054959 T3 PL3054959 T3 PL 3054959T3 PL 14851638 T PL14851638 T PL 14851638T PL 14851638 T PL14851638 T PL 14851638T PL 3054959 T3 PL3054959 T3 PL 3054959T3
Authority
PL
Poland
Prior art keywords
methods
treating fibrotic
fibrotic cancers
cancers
treating
Prior art date
Application number
PL14851638T
Other languages
English (en)
Inventor
Suzanne Bruhn
Elizabeth TREHU
Mark LUPHER
Original Assignee
Promedior Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promedior Inc. filed Critical Promedior Inc.
Publication of PL3054959T3 publication Critical patent/PL3054959T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL14851638T 2013-10-08 2014-10-08 Sposoby leczenia złośliwych nowotworów zwłóknieniowych PL3054959T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361888269P 2013-10-08 2013-10-08
US201461992807P 2014-05-13 2014-05-13
US201462004828P 2014-05-29 2014-05-29
US201462004836P 2014-05-29 2014-05-29
PCT/US2014/059699 WO2015054390A1 (en) 2013-10-08 2014-10-08 Methods for treating fibrotic cancers
EP14851638.8A EP3054959B1 (en) 2013-10-08 2014-10-08 Methods for treating fibrotic cancers

Publications (1)

Publication Number Publication Date
PL3054959T3 true PL3054959T3 (pl) 2020-07-13

Family

ID=52813618

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14851638T PL3054959T3 (pl) 2013-10-08 2014-10-08 Sposoby leczenia złośliwych nowotworów zwłóknieniowych

Country Status (10)

Country Link
US (2) US11020451B2 (pl)
EP (2) EP3718558A1 (pl)
JP (2) JP6636914B2 (pl)
CN (2) CN105792831A (pl)
AU (2) AU2014331954B2 (pl)
CA (1) CA2926418A1 (pl)
ES (1) ES2784234T3 (pl)
PL (1) PL3054959T3 (pl)
RU (2) RU2718056C2 (pl)
WO (1) WO2015054390A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2718056C2 (ru) 2013-10-08 2020-03-30 Промедиор, Инк. Способы лечения фиброзного рака
JP2018512164A (ja) * 2015-04-15 2018-05-17 プロメディオール， インコーポレイテッド 骨髄増殖性障害を処置するための方法
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
US10960006B2 (en) * 2018-01-31 2021-03-30 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
CA3093749A1 (en) * 2018-03-28 2019-10-03 Blade Therapeutics, Inc. Method of treating fibrotic disease
CN108715865B (zh) * 2018-05-28 2021-09-21 福建师范大学 用于提高细胞转染效率的试剂组合物
US20220202803A1 (en) * 2019-04-25 2022-06-30 Clear Creek Bio, Inc. Combination therapies including inhibitors of dihydroorotate dehydrogenase
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
DK0786469T3 (da) 1990-06-11 2006-07-10 Gilead Sciences Inc Nukleinsyreligander
EP0642589A4 (en) 1992-05-11 1997-05-21 Ribozyme Pharm Inc METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION.
AU4769893A (en) 1992-07-17 1994-02-14 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
WO1999004819A1 (en) 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
KR101379364B1 (ko) * 2005-02-08 2014-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 ｍｄａ-7을 포함하는 조성물
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008019199A2 (en) * 2006-06-26 2008-02-14 Macrogenics, Inc. FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AU2007328206B2 (en) * 2006-12-04 2013-08-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
HUE026850T2 (en) * 2007-07-06 2016-08-29 Promedior Inc Methods and preparations for treating mucosal inflammation
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
DK2405929T3 (en) 2009-03-11 2018-08-27 Promedior Inc SAP polypeptide for use in the treatment of autoimmune disorders and graft-versus-host disease
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
US20100266643A1 (en) 2009-04-01 2010-10-21 Willett W Scott Pulmonary and nasal delivery of serum amyloid p
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
DK2987803T3 (en) 2009-06-17 2018-12-17 Promedior Inc SAP variants and their application
US20130195861A1 (en) 2011-12-21 2013-08-01 Promedior, Inc. Serum amyloid p-antibody fusion proteins
JP2015069119A (ja) 2013-09-30 2015-04-13 パナソニック液晶ディスプレイ株式会社 表示装置
RU2718056C2 (ru) 2013-10-08 2020-03-30 Промедиор, Инк. Способы лечения фиброзного рака
JP2018512164A (ja) 2015-04-15 2018-05-17 プロメディオール， インコーポレイテッド 骨髄増殖性障害を処置するための方法

Also Published As

Publication number Publication date
CA2926418A1 (en) 2015-04-16
CN105792831A (zh) 2016-07-20
CN114053395A (zh) 2022-02-18
US20210322515A1 (en) 2021-10-21
ES2784234T3 (es) 2020-09-23
JP2020059752A (ja) 2020-04-16
JP2016539087A (ja) 2016-12-15
AU2014331954A1 (en) 2016-04-21
RU2016117775A (ru) 2017-11-15
RU2016117775A3 (pl) 2018-07-27
EP3054959B1 (en) 2020-01-08
AU2014331954B2 (en) 2020-05-21
RU2718056C2 (ru) 2020-03-30
US20160235812A1 (en) 2016-08-18
AU2020220139A1 (en) 2020-09-10
EP3054959A4 (en) 2017-04-26
US11020451B2 (en) 2021-06-01
JP7140739B2 (ja) 2022-09-21
EP3054959A1 (en) 2016-08-17
WO2015054390A1 (en) 2015-04-16
RU2020111934A (ru) 2020-04-29
JP6636914B2 (ja) 2020-01-29
EP3718558A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
IL292193A (en) Anti-b7–h1 antibodies for the treatment of tumors
SG11201603050TA (en) Methods for treating cancers
HK1220155A1 (zh) 治療癌症的方法
GB201318983D0 (en) Radiotherapy apparatus
EP2945639A4 (en) METHOD FOR THE TREATMENT OF HEART DISEASES
GB201323121D0 (en) Downhole Apparatus
PL3054959T3 (pl) Sposoby leczenia złośliwych nowotworów zwłóknieniowych
HK1213817A1 (zh) 治療癌症的方法
GB201406414D0 (en) Downhole Apparatus
HK1219489A1 (zh) 治療結腸直腸癌的方法
HK1225647A1 (zh) 用於治療癌症的組合物和方法
HK1215164A1 (zh) 處理方法
ZA201606954B (en) Mining apparatus
HK1219513A1 (zh) 治療癌症的方法
HUE048625T2 (hu) Módszer rák kezelésére
EP2941270A4 (en) METHODS FOR TREATING INFLAMMATION
GB201304801D0 (en) Downhole apparatus
GB201402997D0 (en) Improved apparatus
GB201323127D0 (en) Downhole apparatus
GB2500109B (en) Downhole Apparatus
GB2532369B (en) Mousehole apparatus
GB2516659B (en) Structure formation apparatus
GB201321531D0 (en) Treatment for cancers
GB201322764D0 (en) Treating places
GB201300546D0 (en) Cancer Treatment